The Clinical Significance Of Sex Hormone Crosstalk In Estrogen Receptor Positive Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$1,009,006.00
Summary
Breast cancer is mainly a disease in which the sex hormone estrogen stimulates uncontrolled growth. We have recently discovered that other sex hormones, including progesterone and androgen, can redirect the actions of estrogen in breast cancers to halt growth or make a tumour disappear. This study will examine the complex interaction between all three sex hormones to develop new, more effective strategies for treating breast cancer.
Characterising Post Stroke Neuroplasticity In Humans – Identifying A Critical Window For Rehabilitation
Funder
National Health and Medical Research Council
Funding Amount
$764,419.00
Summary
Despite major investment in care for stroke patients, almost all have persisting disability. Stroke causes loss of brain cells that cannot be replaced. Some recovery is possible through compensatory mechanisms. In addition, intact cells around the stroke undergo growth that is critical for recovery. Animal studies suggest these changes take place in a “critical window” after stroke. Applying therapies in this window should improve outcomes. We will use novel approaches to define the “critical wi ....Despite major investment in care for stroke patients, almost all have persisting disability. Stroke causes loss of brain cells that cannot be replaced. Some recovery is possible through compensatory mechanisms. In addition, intact cells around the stroke undergo growth that is critical for recovery. Animal studies suggest these changes take place in a “critical window” after stroke. Applying therapies in this window should improve outcomes. We will use novel approaches to define the “critical window” in patients after strokeRead moreRead less
Pushing AR Toward Better Outcomes In Breast And Prostate Cancers
Funder
National Health and Medical Research Council
Funding Amount
$998,754.00
Summary
Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives ....Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives.Read moreRead less